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Linkage disequilibriumAbstract Background: Regional distribution of adipose tissue is more important than total
amount of body fat in predicting complications associated with obesity. Apolipoprotein B (Apo
B) plays a central role in lipid metabolism.
Aim: To investigate the importance of the XbaI polymorphism of Apo B gene (C7673T) as risk
factor for visceral obesity and its influence on lipid profile.
Subjects and methods: Total of 122 obese adult females (BMIP 30 kg/m2): 56 of them with vis-
ceral obesity (P7 cm by abdominal Ultrasound) and 66 without visceral obesity and 36 age
matched non-obese (BMI 6 25 kg/m2) without visceral obesity were studied. Anthropometric
assessment, body composition, visceral obesity and lipid profile evaluation were attempted. Genetic
analysis of Apo B XbaI was performed using Polymerase Chain Reaction-Restriction Fragment
Length Polymorphism (PCR-RFLP).
Results: Visceral obesity was associated significantly with the presence of the heterozygous (CT)
genotype of the XbaI Apo B gene (p< 0.001). Frequency of homozygous (CC) was significantly the
least genotype found in females with visceral obesity, while homozygote (TT) genotype was more
frequent in those without visceral obesity. T allele (about 70%) was more frequent than C allele
(about 30%) in all groups. Significant lowest values of visceral obesity, triglyceride and HDL-Cpt. Tel.:
178 N.E. Hassan et al.were associated with the presence of (CC) genotype and the highest values were associated with the
presence of the heterozygous (CT) genotype; except HDL-C with (TT) genotype.
Conclusions: Study reveals considerable association of Apo B XbaI gene polymorphism with vis-
ceral obesity and some lipid profile parameters (TG and HDL-C) among Egyptian females.
 2015 Production and hosting by Elsevier B.V. on behalf of Academy of Scientific Research &
Technology.1. Introduction
Worldwide obesity has risen to titanic proportions and has
become a major worldwide health problem [1]. In longitudinal
study published by the Global Burden of Disease Study, the
rate of weight gain expanded most rapidly in the Middle East
particularly Egypt, which rank among the countries in the
world with most overweight people. In Egypt, nearly 70% of
the adult population—about 56.5 million people—are consid-
ered to be overweight. Over the past three decades, the highest
rise in obesity levels among women has been found in Egypt.
Being overweight is more than just an esthetic problem; people
who are overweight have an increased risk of cardiovascular
disease, cancer, diabetes, osteoarthritis, and chronic kidney
disease, with most deaths due to cardiovascular problems,
including heart attack and stroke [2].
A phenomenon that has received increasing attention is the
fact that body shape, andmore specifically the regional distribu-
tion of adipose tissue, is at least as important, if notmore impor-
tant, than the total amount of body fat in predicting disease-
causing complications that have been traditionally associated
with obesity. Literature on regional adipose tissue distribution
andmetabolism has flourished over the past 25 years. They con-
cluded that the proportion of abdominal adipose tissue is a key
correlate; and perhaps driver of the health risk associated with
overweight and obesity. Visceral obesity has now been estab-
lished as being part of a complex phenotype including adipose
tissue storage dysfunction and ectopic triglyceride accumulation
in several sites including the liver [3]. Nazare et al. [4] have
reported ethnic differences in risk and prevalence of metabolic
diseases including obesity. This may be related to patterns of
ethnic-specific body fat distribution.
Dyslipidemias, a group of biochemical disorders, is fre-
quently encountered in obese individuals. The predominant
features of dyslipidemias include increased flux of free fatty
acids (FFA), raised triglyceride (TG) and low high density
lipoprotein cholesterol (HDL-C) levels, a predominance of
small dense (atherogenic) low density lipoprotein cholesterol
(LDL-C) particles and raised apolipoprotein B (Apo B) values.
However, there is a considerable heterogeneity of plasma lipid
profile among obese people. The precise cause of this hetero-
geneity is not entirely clear but has been partly attributed to
the degree of visceral adiposity [5].
The Apo B gene is located on the short arm of chromosome
(2p23-24) [6,7]. Several single nucleotide polymorphisms in the
Apo B gene have been described, including XbaI [8] and
EcoRI [9]. The XbaI polymorphism arises due to a single base
variation in exon 26 (at 2488th position ACC? ACT) of the
Apo B gene that does not lead to change in amino acid
sequence [6]. This polymorphism has been found to be associ-
ated with generalized and regional obesity and an increase in
various lipoprotein subfractions (total cholesterol [TC], lowdensity lipoprotein cholesterol [LDL-C], and triglycerides
[TG]), but the results are conflicting [10].
Because of its central role in lipid transport and metabo-
lism, the examination of the variations of the Apo B gene
could help to explain interindividual variation in lipid levels
and susceptibility to obesity [11].
1.1. Aim of work
This study has been designed to investigate the importance of
the XbaI polymorphism of Apo B gene (C7673T) as risk factor
for visceral obesity and its influence on lipid profile among a
sample of Egyptian obese females.
2. Subjects and methods
2.1. Subjects
This study was a cross-sectional case control one, consisting of
158 females: 122 obese females (BMIP 30 kg/m2) and 36
apparently normal healthy ones (BMI 6 25 kg/m2) serving as
control group; aged 30–62 years (mean: 49.88 ± 5.6). The
obese females were classified into 2 groups: obese with visceral
obesity (56) and obese without visceral obesity (66) using cut-
off point of 7 cm by abdominal Ultrasound. All subjects
enrolled in the study were recruited from outpatient clinic of
the ‘‘Visceral Obesity Management Unit” at ‘‘National
Research Centre”; between October 2011 and December
2013. All obese and controls were subjected to a detailed med-
ical history and information was obtained on demographic
characteristics concerning history and duration of obesity
and medications. Exclusion criteria were: history of smoking,
acute or chronic infections, coronary artery disease, congestive
heart failure, chronic liver disease, diabetic nephropathy, rheu-
matic disease and cancer. The participants were informed
about the purpose of the study and their permission in the
form of written consent was obtained. The protocol was
approved by the ‘‘Ethics Committee” of the ‘‘National
Research Centre”. The agreement reference number is 10/119.
Anthropometry assessment: Anthropometric evaluation was
performed for all obese and control females. Body weight, height
andwaist circumferenceweremeasured following the recommen-
dationsof the InternationalBiological Program [12]. Bodyweight
was determined to the nearest 0.01 kg using a Seca Scale Balance,
with the subject wearing minimal clothing and with no shoes.
Body height was measured to the nearest 0.1 cm using a Holtain
portable Anthropometer. Waist circumference was measured at
the level of the umbilicus with the subject standing; with the face
directed forward and shoulders relaxed; and breathing normally,
using non-stretchable plastic tape to the nearest 0.1 cm. Body
mass index (BMI) was calculated as body weight divided by
height squared (kg/m2).
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TANITA Body composition Analyzer. As specified by the
manufacturer, the unit was calibrated before testing. The par-
ticipant stood on the foot board of the device, while she was
holding the 2 handles carefully; each by one hand at the same
time. By using her sex, age, weight and height approximated to
the nearest unit, the percentage body fat (Fat%: an estimate of
the fraction of the total body mass that is adipose tissue), fat
mass (FM: an estimate of the fraction of the total body weight
that is adipose tissue) and fat free mass (FFM: an estimate of
the fraction of the total body weight that is not adipose tissue),
total body water (TBW) and basal metabolic rate (BMR) were
derived.
Ultrasound (US) examination to each female was done to
evaluate visceral fat at the umbilicus (USVF) in cm. Intra-
abdominal fat thickness measurement was obtained using the
‘‘Medison Sonoace X8” ultrasonography equipment. For the
visceral fat, a 3.5 MHz transducer was transversely positioned
1 cm above the umbilical scar on the abdominal midline,
without exerting any pressure over the abdomen. Visceral fat
thickness attempted corresponding to the measurement in
centimeters between the internal surface of the abdominal
rectus muscle and the posterior aortic wall in the abdominal
midline, during expiration. In the current research, we consid-
ered visceral fat thickness <3 cm as normal, 3 to <7 as border
line and P7 cm with visceral obesity [13]. Then, the obese
females were classified into 2 groups: obese with visceral
obesity (56) and obese without visceral obesity (66) using
cutoff point of 7 cm by Ultrasound. The entire control group
had no visceral obesity (visceral fat thickness <3 cm).Table 1 Genotypes distribution of XbaI Apo B gene in total
obese and lean subjects.
Genotype Total Controls Total obese p value
(N= 158) (N= 36) (N= 122)
N (%) N (%) N (%)
CT 36 (22.8) 8 (22.2) 28 (23) 0.001
TT 94 (59.5) 22 (61.1) 72 (59) 0.000
CC 28 (17.7) 6 (16.7) 22 (18) 0.002
N.B.: **p< 0.01 = highly significant differences.2.2. Laboratory investigations
2.2.1. Sample collection
Five milliliters of venous blood samples was withdrawn after
12–14 h overnight fast into two sterile vacutainer (Becton
Dickinson, NJ, USA); one containing EDTA for assay Apo
B gene variants and the other without additives to separate
serum to assay glucose and lipid profile.
2.2.2. Biochemical analysis
Estimation of lipid profile: Plasma levels of triglycerides (TG),
high density lipoprotein cholesterol (HDL-C) and total choles-
terol (TC) were measured by standardized enzymatic proce-
dures, using kits supplied by Roche Diagnostics (Mannheim,
Germany) on the Olympus AU 400 automated clinical chem-
istry analyzer. Low density lipoprotein cholesterol (LDL-C)
was calculated according to formula of Friedwald et al. [14]:
LDL-C ¼ Total cholesterol Triglycerides=5þHDL-C:
Genotype study of the Apo B XbaI gene polymorphism:
DNA extraction: Genomic DNA was extracted from whole
blood using DNA extraction kit (QIAamp DNA Blood Kit;
Qiagen). The purity of extracted DNA was checked.
Restriction fragment length polymorphism (PCR-RFLP):
The determination of Apo B C7673T polymorphism was done
by the Polymerase Chain Reaction–Restriction Fragment
Length Polymorphism (PCR-RFLP). The amplification reac-
tion was carried out using primers: 50-GGAGACTATTCA
GAAGCTAA-30 and 50-GAAGAGCCTGAAGACTGACT-30
and the following cycling conditions. Each amplificationreaction was performed with 100 ng of genomic DNA; 10 pmol
of each primer; 2 lL of 10 buffer solution; 200 lmol/L each
of dATP, dCTP, dGTP, and dTTP; and 1 U of Taq poly-
merase in a total volume of 20 lL. The DNA fragments were
generated from initial denaturation at 95 C for 2.5 min, fol-
lowed by 30 cycles of denaturation at 94 C for 30 s, annealing
at 58 C for 40 s, and extension at 72 C for 60 s, with final
extension at 72 C for 5 min. The amplification products were
digested with the restriction enzyme XbaI, and the fragments
were separated on a 4% agarose gel [15].
2.2.3. Statistical analysis
The data analysis was carried out using the statistical package
for social science (SPSS) software version 16 (Chicago, IL,
USA). Frequency distribution of the genotypes and alleles
was presented as percentage. All numeric variables were
expressed as mean ± standard deviation (SD). Chi-square test
was used in comparing qualitative data. Comparisons between
3 variables were done using a one way analysis of variance
(ANOVA) test. Statistical significance was set at p< 0.05.
3. Results
The study population consisted of 122 obese females; their
mean age 49.88 ± 5.6 years; and 36 healthy females as control
group with age and sex matching. Comparison between obese
and controls revealed that; BMI, waist circumference, total
cholesterol, LDL-C and triglycerides levels were significantly
higher in obese compared to controls (p< 0.01), while
insignificant difference was found for HDL levels.
3.1. Genotyping results
Comparing distribution of the genotypes of XbaI Apo B gene
between total obese and normal weight subjects revealed that;
the homozygote (TT) genotype was more frequent in both
groups (p= 59% and 61.1% respectively) than the other
two genotypes (CC and CT), while the homozygote (CC) geno-
type was the least frequent in both groups (p= 18% and
16.7% respectively) (Table 1). Dividing obese females accord-
ing to the presence of visceral fat; it was found that visceral
obese status was associated significantly with the presence of
the heterozygous (CT) genotype of the XbaI Apo B gene; as
females carrying (CT) heterozygous represented; 22 out of 56
visceral obese (39.3%), 6 out of 66 (9.1%) obese without
visceral fat and 8 out of 36 (22.2%) normal weight subjects;
with highly significant differences (p< 0.001). On the contrary
the frequency of the homozygous (CC) (the wild type) was
Table 2 Genotype distribution of XbaI Apo B gene in obese;
according to visceral obesity; and lean subjects.








(N= 158) (N= 36) (N= 66) (N= 56)
N (%) N (%) N (%) N (%)
CT 36 (22.8) 8 (22.2) 6 (9.1) 22 (39.3) 0.002
TT 94 (59.5) 22 (61.1) 42 (63.6) 30 (53.6) 0.039
CC 28 (17.7) 6 (16.7) 18 (27.3) 4 (7.1) 0.002
N.B.: **p< 0.01 = highly significant differences.









C 30 27.8 29.5 0.000
T 70 72.2 70.5 0.000
N.B.: **p< 0.01 = highly significant differences.


















C 30 27.8 31.8 26.8 0.019
T 70 72.2 68.2 73.2 0.005
N.B.: **p< 0.01 = highly significant differences.
180 N.E. Hassan et al.significantly the least genotype found in females with visceral
obesity (7.1%) than; in females without visceral obesity
(27.3%) and in lean subjects (17.7%) (p= 0.002). Moreover,
the homozygote (TT) genotype was the most frequent in both
obese without visceral obesity and control groups (63.6% and
61.1% respectively) than the obese with visceral obesity
(53.6%) (Table 2). Example of Electrophoretic separation of
Apo B genotypes (XbaI) among 4 females is presented in
Fig. 1.
Comparing the allele frequencies of XbaI Apo B gene
among the different groups (Tables 3 and 4), revealed that T
allele (about 70%) was more frequent than C allele (about
30%) in all groups under study (total sample, females with vis-
ceral fat, without visceral fat and in control females). This
reflected the higher frequency of T allele than C allele among
females with visceral obesity, while the heterozygous (CT)
genotype was the most frequent among the females with vis-
ceral obesity.
Comparisons of the anthropometric parameters and lipid
profile between various genotype of the Apo B XbaI gene
revealed statistically significant differences in visceral fat mea-
sured by Ultrasound; where the lowest size of visceral obesity
among females subjected to this study was associated with theM              1               2            
Figure 1 Electrophoretic separation of Apo B genotypes (XbaI). Lan
and absence of the restriction site). Lane 2, 3 and 4: CT genotype (hepresence of the wild type (CC) genotype and the highest size
was associated with the presence of the heterozygous (CT)
genotype t(p= 0.017). Concerning lipid profile; the significant
lowest level of triglyceride and HDL-C was associated with the
presence of the wild type (CC) genotype, and the highest level
of triglyceride was associated with the heterozygous (CT)
genotype (p= 0.036); and the highest level of HDL-C was
associated with the presence of the homozygous (TT) genotype
(p= 0.006). However, insignificant statistical differences were
detected between these 3 genotypes of Apo B gene regarding
BMI, waist circumference, all body composition parameters
(Fat%, fat mass, fat free mass, total body water and basal3                  4 
e M: UX174 Marker. Lane 1: CC genotype (wild-type, homozygous
terozygous).
Table 5 Comparisons of the anthropometric parameters and lipid profile between the genotype of Apo B XbaI gene.
Variable CT (N= 36) TT (N= 94) CC (N= 28) p value
Mean ±SD Mean ±SD Mean ±SD
Weight (kg) 98.1500 20.43709 91.1239 23.50827 97.7000 15.47232 0.155
Height (cm) 159.78 5.67255 159.16 8.91737 161.75 8.22091 0.339
BMI (kg/m2) 38.2778 7.39 36.1362 8.66 37.7357 7.93 0.354
Waist circumference (cm) 105.92 15.65 100.30 14.16 106.11 13.68 0.054
US visceral fat (cm) 6.70 2.95 5.87 1.99 5.10 1.84 0.017*
Body composition
FAT (%) 44.29 6.56 41.25 9.70 41.74 10.99 0.269
FM (kg) 44.64 13.75 39.17 17.15 41.70 15.04 0.229
FFM (kg) 54.81 10.70 52.20 9.02 55.29 7.58 0.169
TBW 40.12 7.83 38.21 6.60 40.49 5.55 0.167
BMR (Kcl) 1713.4 329.98 1618.7 286.76 1712.6 220.68 0.135
Lipid profile
Triglycerides (mg/dl) 132.65 57.26 117.68 45.19 101.23 30.24 0.036*
Total cholesterol (mg/dl) 202.71 40.24 214.89 36.58 206.54 39.73 0.262
HDL-C (mg/dl) 47.35 8.87 50.61 9.60 43.85 9.38 0.006**
LDL-C (mg/dl) 128.59 40.00 140.68 37.83 143.00 36.22 0.238
N.B.: *p< 0.05 = significant differences. **p< 0.01 = highly significant differences.
Apolipoprotein B polymorphism distribution 181metabolic rate) and the other parameters of lipid profile (total
cholesterol and LDL-C) (Table 5).
4. Discussion
Genetic epidemiological data demonstrate that; in most cases;
obesity is a multifactorial disorder with genetic contribution in
the range of 40–70%. As obesity is excessive lipid deposition in
the fat tissue, there is good reason to study the association
between excessive fat mass and genetic polymorphisms of lipid
transport proteins. Inherited variations of the apolipoprotein
gene have influence circulating lipid concentration. One of
the most closely monitored genes which may affect lipid meta-
bolism and may predispose to obesity is the gene for Apo B
and XbaI polymorphism [16–18].
The present study, therefore, attempted to investigate the
importance of the XbaI polymorphism of Apo B gene
(C7673T) as risk factor for visceral obesity and its influence
on lipid profile among a sample of Egyptian obese females.
Regarding XbaI polymorphism of Apo B gene (C7673T)
frequency in the current studied sample; both obese and lean,
it was obvious that the homozygote (TT) genotype was the
most frequent; however the homozygote (CC) genotype was
the least frequent.
Rajput-Williams and his colleagues [19], in their analysis
reported that; obesity was associated with XbaI that do not
change the amino acid sequence. They stated that; these RFLP
are likely to be in linkage disequilibrium with nearby func-
tional variation predisposing to obesity. Moreover they postu-
lated that this inherited variation of the apolipoprotein-B gene,
influences circulating cholesterol concentration. The Apo B
XbaI polymorphism was documented to be associated with
obesity and dyslipidemia in North Indian population [20].
Hu et al. [21], support these findings as they postulated that;
Apo B XbaI restriction site may serve as potential genetic
markers affecting BMI and lipid profiles in children from
Guangxi. Among Tunisian population, Apo B restrictionfragment length polymorphisms (XbaI) have been found to
be associated with variation in lipid levels, obesity and/or coro-
nary artery disease [22]. Sa´nchez-Cue´n and his co-workers [23],
agreed with these findings, as they observed a significant asso-
ciation of Apo B XbaI gene polymorphism with obesity and
serum lipid levels in Mexican population. While contradictory
results were also available; Misra and his colleagues [24]
reported that Apo B XbaI gene polymorphism did not associ-
ate with obesity in Asian Indian. Srivastava et al. [10] also
coincide with this result as they showed that there was an
insignificant difference in the genotype and allele frequencies
of Apo B XbaI polymorphism between obese and non-obese
subjects.
The current study revealed that there were insignificant
associations between different genotypes of the Apo B XbaI
polymorphism and the studied anthropometric parameters
(Weight, Height, BMI, waist circumferences, Fat%, BMR,
FM, FFM and TBW) while, the current study demonstrated
an influence of XbaI polymorphism of Apo B gene on visceral
obesity only. The most important finding emerging from the
current study was that the frequency of the heterozygous geno-
type (CT) was significantly higher in obese with visceral obe-
sity than in the other two groups (lean and obese with no
visceral fat), (p= 0.002) while the homozygous wild type
genotype (C/C), lacking the XbaI site was more frequent in
obese patients without visceral fat (p= 0.017).
Ryo and his colleagues [25] confirmed that regional adipose
tissue parameters, especially visceral tissue mass are more clo-
sely associated with physiological and pathological processes
than total adipose tissue mass.
The genetic determination of lipidemia has been intensively
investigated since 1980s. Apo B gene is of particular interest
since its protein product plays a crucial role in the formation
and clearance of plasma LDL particles. The first papers
addressing this topic [26,27] referred to the T allele as a disad-
vantageous one. The above authors reported an association
between the allele and increased levels of triacylglycerols
182 N.E. Hassan et al.(TG) and total cholesterol (TC). Talmud et al. [28] demon-
strated, in a randomly selected population sample, an associa-
tion between the (CC) genotype and low TC levels. In a study
conducted by Tybjaerg-Hansen et al. [29], the highest levels of
LDL-cholesterol were shown in TT homozygote with coronary
artery disease (CAD). In hyperlipidemic patients TT homozy-
gotes were found with increased levels of fasting TG [30].
However, the subsequent studies produced opposite results; a
group of CC homozygotes showed the highest levels of TC
[29] or LDL-cholesterol [31]. Hansen et al. [32] found the high-
est levels of TC in CC homozygotes whose body mass index
(BMI) was <25. A dietary study of Friedlander et al. [33] indi-
cated a more marked increase in blood lipid concentrations in
individuals with TT receiving a high-cholesterol diet. The rela-
tionship between the XbaI polymorphism of the Apo B gene
and serum lipid levels was not documented in the Japanese
[34] and Chinese [35] population. This may be due to the much
lower cholesterol concentration and a lower incidence of the
(T) allele compared to European population.
In the current study, high statistical significant associations
of genotypes were shown with; triglyceride concentrations
(TG) (p= 0.036) and HDL-C (p= 0.006) levels among the
female samples analyzed. The Wild type homozygous genotype
was significantly associated with lower TG serum levels
(p = 0.036). While there was no association between Apo B
gene polymorphism and levels of the other lipid parameters
(total cholesterol and LDL). Current study confirms the earlier
association between the absence of the XbaI cutting site and
the higher TG levels [36].
Hypertriglyceridemia may be the major cause of the other
lipid abnormalities since it will lead to delayed clearance of
the TG-rich lipoproteins and formation of small dense LDL-
C. The mechanism underlying the association between the
Apo B XbaI polymorphism and lipid levels is unknown. It
could be explained by variation in the synthetic rate of Apo
B and Apo B containing lipoproteins, or variation in the
removal rate of the Apo B in individuals with different Apo
B XbaI genotypes. This effect might be due to the slightly
lower LDL catabolic rate in the individuals with the XbaI cut-
ting site. Also, variation in the Apo B gene could influence
body fat deposition by affecting the delivery of triglycerides
to adipose tissue by Apo B-containing VLDL particles. Other
clarification may be; as serum concentration of lipids is highly
variable during the day, and the weakness of the association
might be due to the fact that serum lipids levels are generally
measured in the fasting state during which they reach the
lowest levels [37]. Moreover it has been demonstrated that
the XbaI polymorphism modifies dietary fat and cholesterol
responses in individuals with the XbaI cutting site [38].
There may be several reasons for the controversy or polar-
ity observed in various studies. A simple explanation could be
that Apo B XbaI polymorphism exhibits population specific
variation, which may be due to gene and environment
interactions with variation at the Apo B gene to determine
an individual’s plasma lipid and lipoprotein levels. There is
general agreement that genetic heterogeneity across races
and ethnicities exists in the Apo B gene polymorphisms
[39]. Apo B XbaI polymorphism does not lead to changes
in the amino acid sequence and cannot be implicated at the
structure level. It is possible that some other polymorphism
in its vicinity might be present, which is in linkage disequilib-
rium with Apo B XbaI polymorphism and accountable forthe observed association with obesity and lipid levels in other
studies. Saha et al. [35], showed a strong disequilibrium
between ins/del polymorphism and the XbaI polymorphism
of Apo B gene. Moreover, gene–environment interaction
may also be responsible for the inconsistency of data due
to differences in the diet and lifestyle of populations of
various parts of the world [40].
Studies with a larger sample size are necessary and further
investigation is needed to confirm or refute the role of this
polymorphism and/or other polymorphisms in relation to obe-
sity (visceral obesity). In conclusion, the genetic diagnosis and
molecular characterization of Apo B gene mutations will allow
a better assessment of response to treatment, prevention and
family screening in these subjects.
5. Conclusion
Visceral obesity was associated significantly with the presence
of the heterozygous (CT) genotype of the XbaI Apo B gene; in
spite of the finding that the homozygote (TT) genotype was the
most frequent and the homozygote (CC) genotype was the
least frequent. There were significant associations between
CT genotype and visceral obesity, triglycerides and HDL-C.Acknowledgments
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